Editorial & Opinion
Alternative Dosing Schedules of Azacitidine: A Real-World Study Across South American Centers.
| العنوان: | Alternative Dosing Schedules of Azacitidine: A Real-World Study Across South American Centers. |
|---|---|
| المؤلفون: | Castelo L; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil; Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil. Electronic address: fcastelo.lucas@gmail.com., da Silva WF; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil., Lincango M; Laboratorio de Genética Hematológica, Instituto de Medicina Experimental (IMEX-CONICET)/ Academia Nacional de Medicina, Buenos Aires, Argentina., Buccheri V; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil., Perusini A; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Arbelbide J; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Iastrebner M; Sanatorio Sagrado Corazón, Buenos Aires, Argentina., Gonzalez J; Hospital General de Agudos Carlos Durand, Buenos Aires, Argentina., Pereyra P; Hospital Nacional Alejandro Posadas, El Palomar, Provincia de Buenos Aires, Argentina., Pereira TDM; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil., Marchi LL; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil., Rocha V; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil., Belli CB; Laboratorio de Genética Hematológica, Instituto de Medicina Experimental (IMEX-CONICET)/ Academia Nacional de Medicina, Buenos Aires, Argentina., Velloso EDRP; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil; Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil. |
| المصدر: | Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Jun; Vol. 24 (6), pp. 407-411. Date of Electronic Publication: 2024 Feb 14. |
| نوع المنشور: | Letter |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2011-: [New York] : Elsevier Original Publication: Dallas, Tex. : Cancer Media Group |
| مواضيع طبية MeSH: | Azacitidine*/administration & dosage , Azacitidine*/therapeutic use, Humans ; Male ; Female ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/therapeutic use ; South America ; Drug Administration Schedule ; Middle Aged ; Aged |
| مستخلص: | Competing Interests: Disclosures The authors have no competing interest to declare that are relevant to the content of this article. |
| المشرفين على المادة: | M801H13NRU (Azacitidine) 0 (Antimetabolites, Antineoplastic) |
| تواريخ الأحداث: | Date Created: 20240310 Date Completed: 20240530 Latest Revision: 20240917 |
| رمز التحديث: | 20240917 |
| DOI: | 10.1016/j.clml.2024.02.003 |
| PMID: | 38462425 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2152-2669 |
|---|---|
| DOI: | 10.1016/j.clml.2024.02.003 |